Olsson, Bob
Alberg, Lars
Cullen, Nicholas C.
Michael, Eva
Wahlgren, Lisa
Kroksmark, Anna-Karin
Rostasy, Kevin
Blennow, Kaj
Zetterberg, Henrik
Tulinius, Már
Funding for this research was provided by:
Vetenskapsrådet (NA)
Knut och Alice Wallenbergs Stiftelse (NA)
Torsten Söderbergs Stiftelse (NA)
FP7 Ideas: European Research Council (681712)
Article History
Received: 7 January 2019
Revised: 11 April 2019
Accepted: 17 May 2019
First Online: 23 May 2019
Compliance with ethical standards
:
: MT was the Principal Investigator for Sweden in the IONIS/Biogen nusinersen phase 3 Clinical trials. MT has also served as Consultant and speaker for Biogen and PTC Therapeutics and served on advisory boards for Biogen, PTC Therapeutics, Avexis, and Sarepta. KB has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, EliLilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics. HZ has served on scientific advisory boards for Roche Diagnostics, Samumed, CogRx, and Wave and has received travel support from Alzecure. KB and HZ are co-founders of Brain Biomarkers Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr. Bob Olsson, Dr. Lars Alberg, Mr. Nicholas C. Cullen, Dr. Eva Michael, Ms. Lisa Wahlgren, and Dr. Anna-Karin Kroksmark report no disclosures.
: All the procedures conducted with the participants of this study were carried out according to the Declaration of Helsinki.
: The study was approved by the Regional Ethics Committee in Gothenburg and all parents gave informed consent.